MHRA Halts New Prescriptions of a Rare Disease Drug Over Trial Data Doubts
What happened
On 1 September 2026 the UK's medicines regulator, the MHRA, announced the result of a review into a medicine called Avacopan Vifor. It was previously sold under the name Tavneos. The regulator concluded that the evidence no longer supports a positive balance of benefits against risks. In plain terms: it is no longer confident the medicine works as well as the original approval assumed. The reason is unusual. This is not a newly discovered side effect. The concern is about the integrity and reliability of data from the main clinical study that supported the medicine being licensed in the first place. The MHRA decided that study can no longer be relied on to show the drug is effective. As a result, from 1 September 2026 no new patients should be started on it. Patients already taking it can continue during a managed withdrawal period of about six months, so they and their specialists have time to plan an alternative. The plan is to revoke the marketing authorisation on 1 March 2027. Julian Beach, MHRA Executive Director for Healthcare Quality and Access, said: "Patient safety is our highest priority. Following a thorough review of the available evidence, we have concluded that the data supporting the efficacy of Avacopan Vifor is no longer sufficiently reliable to support a positive benefit-risk balance."
Why this matters
This medicine is used for two rare autoimmune conditions: granulomatosis with polyangiitis, usually shortened to GPA, and microscopic polyangiitis, or MPA. Both are types of vasculitis, where the immune system attacks small blood vessels. They can damage the kidneys, lungs and other organs, and they can be life-threatening if not treated. So the people affected are not a large group, but they are people with a serious illness who were relying on this treatment. Being told that a medicine you take is being withdrawn is unsettling, and it is reasonable to feel worried. There is a bigger point here too, and it is actually a reassuring one. Regulators do not only look at medicines before approval and then walk away. They keep reviewing them. When something does not hold up, they act, even when that means reversing an earlier decision. That is the system working rather than failing. It is uncomfortable, but a regulator willing to revisit its own approvals is safer than one that is not.
What the evidence actually says
It is important to be precise about what the MHRA has and has not said, because the difference matters a lot to patients. The MHRA has not said the medicine has been found to be dangerous. It has not announced a new safety scare or a newly identified harm. What it has said is that the pivotal trial data underpinning the claim that the drug works can no longer be relied upon. That is a question about proof of benefit, not about proof of harm. When a regulator cannot be confident a medicine helps, then any risk it carries, however modest, stops being worth taking. That is how a benefit-risk balance tips. This is also why the withdrawal is being managed over six months rather than immediately. If the medicine were considered acutely dangerous, the response would look very different and much faster. Instead, the MHRA has left room for specialists to move patients across carefully. Existing safety monitoring stays in place during that period. That includes liver function tests and white blood cell counts for people still taking it. One more honest note: there are other treatments used for GPA and MPA, and decisions about them are specialist decisions. This article cannot tell you which alternative is right for any individual, and nobody should read it as suggesting one.
Qurexa perspective
We handle prescription supply and medication adherence, so we want to underline one specific thing in the MHRA's advice, because it is the part most likely to be misread. If you are currently taking this medicine, do not stop it on your own after reading a headline. That instruction comes from the regulator itself: patients should not stop without speaking to their specialist. Stopping a treatment for vasculitis suddenly and without a plan can allow the underlying disease to flare, and that carries its own real risk. The six-month window exists precisely so that changes happen in an orderly way, with medical supervision. In our experience, the moments when medicines go wrong are usually transition moments. A treatment changes, a repeat prescription does not get updated, and a gap opens up that nobody noticed. If your treatment is being switched over the coming months, it is worth checking that your repeat prescription record has actually been changed, and that you know what you are collecting and when.
Practical advice
If this affects you or someone you care for, here is a sensible order to do things in. If you take this medicine now: keep taking it as prescribed until you have spoken to your specialist team. Contact them, or your GP practice, to ask about a review. You do not need to treat this as an emergency, but do not leave it for months either. The managed withdrawal period is roughly six months from 1 September 2026. If you were about to start it: you will not be started on it now. Your specialist should discuss alternatives with you. If you are a carer or family member: help make the call if the person you care for finds phone appointments difficult, and write down what the specialist says. It is easy to lose details in a stressful conversation. Questions worth asking your specialist: what are you switching me to, and why that one? How quickly will the change happen? What should I watch out for during the switch? Who do I contact if my symptoms come back? And for everyone else reading this: the practical lesson is broader. If you ever see news that a medicine you take is being reviewed or withdrawn, the right first move is always to contact a healthcare professional rather than to stop the medicine yourself.
What to know
On 1 September 2026 the MHRA concluded that Avacopan Vifor, formerly Tavneos, no longer has a positive benefit-risk balance. It is used for two rare types of vasculitis, GPA and MPA. The reason is doubt about the reliability of the data from the pivotal clinical trial, not a new safety alert. No new patients should be started on it from 1 September 2026. Existing patients continue through a managed withdrawal of around six months, with the marketing authorisation due to be revoked on 1 March 2027. Existing monitoring, including liver function and white blood cell tests, continues meanwhile. The single most important message: if you take it, do not stop on your own. Speak to your specialist. More widely, this is an example of a regulator revisiting an old decision when the evidence behind it stopped standing up. That is worth knowing about, even if this particular medicine will never affect you. Sources: MHRA, "MHRA concludes review of Avacopan Vifor following reassessment of benefit-risk balance", 1 September 2026, https://www.gov.uk/government/news/mhra-concludes-review-of-avacopan-vifor-following-reassessment-of-benefit-risk-balance | Medicines and Healthcare products Regulatory Agency, https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency | NHS, "Vasculitis", https://www.nhs.uk/conditions/vasculitis/ This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. Never stop or change a prescribed medicine because of something you have read online. If you take this medicine, contact your specialist team or GP practice.
Related articles
Seven-Minute Cholesterol Checks Are Coming to About 100 High Street Pharmacies
NHS England announced on 31 August 2026 that around 100 high street pharmacies in England will start offering cholesterol checks that take about seven minutes.…
Flu Jabs Begin for Children and Pregnant Women as NHS Starts Winter Push
The NHS in England has started this winter's flu vaccination programme. From 1 September 2026, school-aged children and pregnant women can get their free flu ja…